Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer

OncoTargets and Therapy

Volumn 4, Issue , 2011, Pages 209-215

  Deshpande, Hari ^a,c   Marler, Vicky ^c   Sosa, Julie Ann ^b,c  

^a Department of Medicine ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

Medullary thyroid cancer; Vandetanib; ZD6474

Indexed keywords

CABOZANTINIB; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN RECEPTOR;

ACNE; ADVANCED CANCER; ANOREXIA; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; COST UTILITY ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLICULITIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LOCAL METASTASIS; MACULOPAPULAR RASH; MEDULLARY THYROID CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SUDDEN DEATH; THYROID CANCER; TORSADE DES POINTES;

EID: 84868199576     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S17422     Document Type: Review

References (35)

1. Carling T, Udelsman R. Thyroid tumors. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
2. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab. 1959; 19(1):152-161.
3. Friedell GH, Carey RJ, Rosen H. Familial thyroid cancer. Cancer. 1962; 15:241-245.
4. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med. 1961;31(1):163-166.
5. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968;47(5):371-409.
6. Sakorafas GH, Friess H, Peros G. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer. 2008;15(4):871-884.
7. B Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12):5658-5671.
8. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77(8):1556-1565.
9. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134-2142.
10. Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol. 1990;116(1):21-23.
11. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008;20(1):19-24.
12. Schimke RN, Hartmann WH. Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Ann Intern Med. 1965;63(6):1027-1039.
13. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell. 1985;42(2):581-588.
14. Eng C. RET protooncogene in the development of human cancer. J Clin Oncol. 1999;17(1):380-393.
15. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010;20(8):863-871.
16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
17. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16): 4645-4655.
18. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284-7290.
19. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007;16(2):239-249.
20. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16(8):1391-1397.
21. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1(9):1002-1009.
22. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767-772.
23. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6): 2664-2671.
24. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized double blind Phase III trial (ZETA) [abstract]. J Clin Oncol. 2010;28(15 Suppl): Abst 5503.
25. Vandetanib (ZD6474) tablets Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document 02 December 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdf. Accessed October 31, 2011.
26. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 1987;10(3):303-310.
27. Matuszczyk A, Petersenn S, Voigt W, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2010;42(1):61-64.
28. Gilliam LK, Kohn AD, Lalani T, et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid. 2006;16(8): 801-810.
29. Kurzrock R, Cohen EE, Sherman SI, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET [abstract]. J Clin Oncol. 2010;28(15 Suppl):Abst 5502.
30. Salgia R, Sherman S, Hong DS, et al. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies including a subgroup of patients with medullary thyroid cancer (MTC) [abstract]. J Clin Oncol. 2008; 26 Suppl:Abst 3522.
31. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009; 27(23):3794-3801.
32. Deshpande HA, Gettinger S, Sosa JA. Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid. 2010;4:43-48.
33. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708-4713.
34. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14): 2323-2330.
35. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21): 5260-5268.